EC Number |
Recommended Name |
Source Tissue |
Reference |
---|
3.1.1.32 | phospholipase A1 |
blood plasma |
- |
691842 |
3.1.1.34 | lipoprotein lipase |
blood plasma |
- |
691193, 692579, 692691, 693511, 694937, 715839, 729143, 751275, 751467 |
3.1.1.34 | lipoprotein lipase |
blood plasma |
heparin releases LPL from its in vivo binding sites allowing it to enter the blood plasma |
693188 |
3.1.1.34 | lipoprotein lipase |
blood plasma |
in vivo administration of adrenaline and acute stress causes an increase in plasma lipoprotein lipase activity |
681271 |
3.1.1.34 | lipoprotein lipase |
blood plasma |
limb muscle, increase of enzyme activity and mRNA level upon chronic and acute stress |
665345 |
3.1.1.34 | lipoprotein lipase |
blood plasma |
measurable LPL activity is present only in postheparin plasma |
681270 |
3.1.1.4 | phospholipase A2 |
blood plasma |
- |
693485 |
3.1.1.47 | 1-alkyl-2-acetylglycerophosphocholine esterase |
blood plasma |
- |
667771, 669511, 670952, 678391, 679309, 690673 |
3.1.1.47 | 1-alkyl-2-acetylglycerophosphocholine esterase |
blood plasma |
enzyme associated with low-density lipoprotein and high-density lipoprotein |
669511 |
3.1.1.47 | 1-alkyl-2-acetylglycerophosphocholine esterase |
blood plasma |
main part of enzyme associated with low-density lipoprotein, small portion of enzyme associated with high-density lipoprotein |
670731 |
3.1.1.47 | 1-alkyl-2-acetylglycerophosphocholine esterase |
blood plasma |
pPAF-AH activity is significantly lower in HCV patients than in controls. Patients who cleared HCV after antiviral treatment show a complete restoration of pPAF-AH activity |
681670 |
3.1.1.55 | acetylsalicylate deacetylase |
blood plasma |
venous blood, similar aspirin esterase activity in frailty phenotype as in young/healthy phenotype |
697716 |
3.1.1.7 | acetylcholinesterase |
blood plasma |
- |
666538, 709675 |
3.1.1.8 | cholinesterase |
blood plasma |
- |
663771, 665984, 666699, 678430, 679471, 682920, 683010, 691741, 691743, 691744, 691747, 691748, 695283, 702676, 713701, 714409, 714416, 714705, 714777, 714925, 716278, 728949, 729566, 749836, 749864, 751194, 751199, 751208, 751209, 751284, 751379, 751817 |
3.1.1.84 | cocaine esterase |
blood plasma |
- |
716278 |
3.1.2.12 | S-formylglutathione hydrolase |
blood plasma |
- |
691781 |
3.1.21.1 | deoxyribonuclease I |
blood plasma |
blood plasma of 40 non-pregnant women, 40 healthy pregnant women (over 37 weeks) and 40 pregnant women with a diagnosis of intrauterine growth restriction |
750009 |
3.1.3.1 | alkaline phosphatase |
blood plasma |
- |
681634, 750060 |
3.1.3.26 | 4-phytase |
blood plasma |
- |
94776 |
3.1.4.1 | phosphodiesterase I |
blood plasma |
- |
-, 208376, 208383, 730060 |
3.1.4.11 | phosphoinositide phospholipase C |
blood plasma |
- |
679670 |
3.1.4.12 | sphingomyelin phosphodiesterase |
blood plasma |
a secreted, zinc-activated form of ASM is found in the plasma which plays an important role in the development of atherosclerosis |
692274 |
3.1.4.39 | alkylglycerophosphoethanolamine phosphodiesterase |
blood plasma |
- |
-, 695455, 697490, 701638, 703366, 704356, 706577, 729349 |
3.1.4.39 | alkylglycerophosphoethanolamine phosphodiesterase |
blood plasma |
high phosphodiesterase Ialpha/autotoxin levels |
696397 |
3.1.4.50 | glycosylphosphatidylinositol phospholipase D |
blood plasma |
- |
693991 |
3.1.4.50 | glycosylphosphatidylinositol phospholipase D |
blood plasma |
plasma enzyme levels are significantly lower in patients with ruptured compared nonruptured abdominal aortic aneurysm which is a result of hemodilution due to hemorrhage in patients with ruptured abdominal aortic aneurysm. The plasma enzyme levels are similar in patients with nonruptured abdominal aortic aneurysm compared to the controls without aneurysm |
729848 |
3.1.6.13 | iduronate-2-sulfatase |
blood plasma |
- |
691079, 709387 |
3.1.6.2 | steryl-sulfatase |
blood plasma |
plasma estradiol levels are stimulated 3 days ahead of inhibitor application with pregnant mare's serum gonadotropin (PMSG) |
691817 |
3.1.6.4 | N-acetylgalactosamine-6-sulfatase |
blood plasma |
- |
679285 |
3.1.8.1 | aryldialkylphosphatase |
blood plasma |
- |
35209, 35216, 646508, 646513, 678376, 678464, 681730, 690495, 690957, 691855, 693321, 693517, 695193, 714002, 750290 |
3.2.1.17 | lysozyme |
blood plasma |
- |
751265, 751451 |
3.2.1.18 | exo-alpha-sialidase |
blood plasma |
- |
678992 |
3.2.1.22 | alpha-galactosidase |
blood plasma |
- |
729607, 750344 |
3.2.1.31 | beta-glucuronidase |
blood plasma |
- |
710621 |
3.2.1.35 | hyaluronoglucosaminidase |
blood plasma |
- |
699185 |
3.2.1.49 | alpha-N-acetylgalactosaminidase |
blood plasma |
- |
665838, 707033 |
3.2.1.51 | alpha-L-fucosidase |
blood plasma |
- |
699825 |
3.3.2.10 | soluble epoxide hydrolase |
blood plasma |
- |
700601, 709248 |
3.3.2.11 | cholesterol-5,6-oxide hydrolase |
blood plasma |
- |
753646 |
3.3.2.6 | leukotriene-A4 hydrolase |
blood plasma |
- |
731424 |
3.4.11.14 | cytosol alanyl aminopeptidase |
blood plasma |
- |
680075 |
3.4.11.2 | membrane alanyl aminopeptidase |
blood plasma |
- |
665836 |
3.4.11.2 | membrane alanyl aminopeptidase |
blood plasma |
in women with active exposure to tobacco smoke, a higher activity level of alanine aminopeptidase and gamma-glutamyltransferase in the plasma is found |
753446 |
3.4.11.21 | aspartyl aminopeptidase |
blood plasma |
- |
680075 |
3.4.11.6 | aminopeptidase B |
blood plasma |
- |
665836 |
3.4.11.7 | glutamyl aminopeptidase |
blood plasma |
- |
665836 |
3.4.11.7 | glutamyl aminopeptidase |
blood plasma |
while hyperthyroid rats exhibit lower levels of plasma AP A activity than controls, the kidney of hyperthyroid animals expresses significantly higher AP A than controls and hypothyroid animals. A discrepancy between the high expression of AP A in kidney of hyperthyroid rats and the low activity of AP A measured in plasma and kidney of hyperthyroid animals is found. The posttranslational influence of environmental biochemical factors may be in part responsible for that divergence |
-, 753433 |
3.4.11.9 | Xaa-Pro aminopeptidase |
blood plasma |
- |
699834 |
3.4.13.9 | Xaa-Pro dipeptidase |
blood plasma |
- |
707644 |
3.4.13.9 | Xaa-Pro dipeptidase |
blood plasma |
prolidase activity in blood plasma is about 6% as great as in erythrocytes |
695908 |
3.4.14.5 | dipeptidyl-peptidase IV |
blood plasma |
- |
-, 664313, 664847, 677897, 678597, 678622, 678634, 678658, 679662, 679663, 679668, 680234, 681319, 681325, 696134, 696136, 696668, 696670, 696746, 697297, 697436, 697489, 697519, 697522, 697550, 697551, 697556, 697560, 697561, 697763, 697764, 697770, 697773, 698213, 698335, 699445, 699748, 699944, 699985, 700399, 700400, 700615, 701376, 702514, 702623, 702941, 703552, 703784, 704840, 705754 |
3.4.14.5 | dipeptidyl-peptidase IV |
blood plasma |
DPP4 activity is higher in whole blood than in the blood plasma |
703300 |
3.4.14.5 | dipeptidyl-peptidase IV |
blood plasma |
in blood plasma DPIV represents 78% of the total Gly-L-Pro-4-nitroanilide-hydrolyzing activity |
697386 |
3.4.15.1 | peptidyl-dipeptidase A |
blood plasma |
- |
653580, 667885, 679708, 695446, 697774, 697821, 697822, 698423, 699887, 701190, 732968 |
3.4.17.20 | Carboxypeptidase U |
blood plasma |
- |
647563, 651987, 653008, 653977, 667916, 668287, 668290, 670058, 670060, 670291, 670474, 670939, 670940, 670944, 696559, 696925, 696926, 697399, 697427, 697552, 697622, 697721, 697791, 698144, 698377, 699864, 699870, 700206, 701278, 701295, 707122, 707597, 709725, 709727, 754518 |
3.4.17.20 | Carboxypeptidase U |
blood plasma |
activity levels are higher in patients with acute myocardial infarction than in controls |
754511 |
3.4.17.20 | Carboxypeptidase U |
blood plasma |
CPU circulates in plasma as an inactive precursor, designated procarboxypeptidase U (proCPU or TAFI) from which it is released after activation by thrombin, plasmin, or the thrombin-thrombomodulin complex |
707113 |
3.4.17.20 | Carboxypeptidase U |
blood plasma |
in all individuals, carboxypeptidase U generation is biphasic. Marked inter-individual differences are present and a reference range is determined. The endogenous Carboxypeptidase U generation potential is the composite effect of multiple factors. With respect to the first carboxypeptidase U activity peak characteristics, a correlations with baseline proCPU concentration, proCPU Thr325Ile polymorphism, time to clot initiation and the clot lysis time is detected. The second CPU peak is related with baseline proCPU levels and with the maximum turbidity of the clot lysis profile |
755576 |
3.4.17.20 | Carboxypeptidase U |
blood plasma |
maternal and fetal |
670949 |
3.4.17.20 | Carboxypeptidase U |
blood plasma |
TAFI circulates at a concentration of 0.004-0.015 mg/ml |
653977 |
3.4.17.21 | Glutamate carboxypeptidase II |
blood plasma |
the enzyme is present in human blood, and its concentration within a healthy population varies between 1.3 and 17.2 ng/ml |
755286 |
3.4.17.23 | angiotensin-converting enzyme 2 |
blood plasma |
- |
679707, 681178, 753896, 763771 |
3.4.17.23 | angiotensin-converting enzyme 2 |
blood plasma |
ACE2 circulates in human plasma, but its activity is suppressed by the presence of an endogenous inhibitor |
679708 |
3.4.17.23 | angiotensin-converting enzyme 2 |
blood plasma |
no or very low ACE2 in healthy individuals. ACE2 may be upregulated in subjects with cardiovascular disease |
668897 |
3.4.17.23 | angiotensin-converting enzyme 2 |
blood plasma |
of patients with obstructive coronary artery disease |
755175 |
3.4.17.3 | lysine carboxypeptidase |
blood plasma |
- |
653008, 653145, 668070, 695421, 698988, 700246 |
3.4.18.1 | cathepsin X |
blood plasma |
- |
665927 |
3.4.19.12 | ubiquitinyl hydrolase 1 |
blood plasma |
the median concentration of UCHL1 in the blood plasma of boys with cryptorchidism, is 5folds higher than in boys with inguinal hernia, whose testicles are located in the scrotum. Significant difference between UCHL1 levels in boys with cryptorchidism up to 2 years old, and above 2 years old. Older boys, whose testicles since birth are located in the inguinal pouch or in the abdominal cavity, have higher concentration of UCHL1 in their blood plasma, than boys from younger group |
755164 |
3.4.21.104 | mannan-binding lectin-associated serine protease-2 |
blood plasma |
- |
666927, 708201, 708697, 709344, 718181 |
3.4.21.118 | kallikrein 8 |
blood plasma |
- |
697372 |
3.4.21.20 | cathepsin G |
blood plasma |
- |
731354 |
3.4.21.21 | coagulation factor VIIa |
blood plasma |
- |
654496, 654508, 654613, 656000, 657386, 668158, 669415, 717171, 717385, 755547 |
3.4.21.22 | coagulation factor IXa |
blood plasma |
- |
669217, 669228, 693470, 717800, 717964, 718138, 732043, 732094 |
3.4.21.26 | prolyl oligopeptidase |
blood plasma |
- |
693500 |
3.4.21.27 | coagulation factor XIa |
blood plasma |
- |
652338, 669347, 669428, 693547, 695184, 707856, 709721, 709722, 710438, 710600, 717420, 717844, 718042, 753068 |
3.4.21.27 | coagulation factor XIa |
blood plasma |
from patients with aortic stenosis |
717416 |
3.4.21.34 | plasma kallikrein |
blood plasma |
- |
695990, 709045, 717809, 731539, 732147, 732785, 732928, 732931, 732933, 752857, 753288 |
3.4.21.34 | plasma kallikrein |
blood plasma |
activity in plasma of patients with pemphigus foliaceus is significantly increased compared with controls |
668107 |
3.4.21.35 | tissue kallikrein |
blood plasma |
- |
699317, 707431, 717095, 731671 |
3.4.21.35 | tissue kallikrein |
blood plasma |
activity in plasma of patients with pemphigus foliaceus is significantly increased compared with controls |
668107 |
3.4.21.37 | leukocyte elastase |
blood plasma |
- |
697044, 697960, 698504, 700892, 701184 |
3.4.21.38 | coagulation factor XIIa |
blood plasma |
- |
691466, 701286, 709176, 731674, 732402, 753067, 753073, 753224, 753351, 95410, 95419 |
3.4.21.38 | coagulation factor XIIa |
blood plasma |
the high plasma titer of factor XII observed in estrogen-treated and prolactin-treated rats is caused by enhanced hepatic expression of both transcriptional and translational levels, as well as by increased secretion of factor XII |
95417 |
3.4.21.41 | complement subcomponent C1r |
blood plasma |
- |
717805, 732102 |
3.4.21.42 | complement subcomponent C1s |
blood plasma |
- |
652681, 753071 |
3.4.21.43 | classical-complement-pathway C3/C5 convertase |
blood plasma |
- |
649815, 652460, 753663 |
3.4.21.45 | complement factor I |
blood plasma |
- |
669058 |
3.4.21.46 | complement factor D |
blood plasma |
- |
668074, 668289 |
3.4.21.47 | alternative-complement-pathway C3/C5 convertase |
blood plasma |
- |
649815, 707846, 709360, 710040, 732819, 753663 |
3.4.21.5 | thrombin |
blood plasma |
- |
667603, 701289, 707386, 707408, 707921, 707941, 707944, 707945, 708152, 708153, 708154, 708178, 708274, 708363, 709161, 709693, 710224, 710610, 710634, 717955 |
3.4.21.6 | coagulation factor Xa |
blood plasma |
- |
666180, 695438, 698769, 699159, 708505, 709730, 710601, 710609, 732376, 752614, 754844, 81416, 81419, 81423 |
3.4.21.61 | Kexin |
blood plasma |
- |
707332, 732078 |
3.4.21.61 | Kexin |
blood plasma |
in healthy volunteers, there is no significant difference in plasma PCSK9 measured between men and women |
710641 |
3.4.21.69 | Protein C (activated) |
blood plasma |
- |
-, 717690, 731565, 732240, 732604, 753070 |
3.4.21.69 | Protein C (activated) |
blood plasma |
protein C circulates in plasma as an inactive zymogen and is activated by thrombin bound to the endothelium associated transmembrane receptor thrombomodulin |
718418 |
3.4.21.7 | plasmin |
blood plasma |
- |
669210, 731263, 732904 |
3.4.21.7 | plasmin |
blood plasma |
plasma obtained from coronary artery disease patients contains 1.7fold more plasmin compared to controls |
670064 |
3.4.21.73 | u-Plasminogen activator |
blood plasma |
- |
-, 669742, 696963, 699162, 731237 |
3.4.21.73 | u-Plasminogen activator |
blood plasma |
patients with common variable immunodeficiency show increased levels of plasma uPA |
697422 |
3.4.21.76 | Myeloblastin |
blood plasma |
PR3 plasma concentrations are increased in patients with liver steatosis |
754755 |